Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amgen Inc. (AMGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biotechnology issuer and a component of the Dow Jones Industrial Average and Nasdaq-100 Index, Amgen uses SEC filings to report financial results, material events and other information relevant to shareholders.
Amgen’s Form 8-K filings illustrate how the company communicates quarterly performance. For example, 8-K reports dated August 5, 2025 and November 4, 2025 describe second and third quarter earnings press releases, including unaudited results of operations and financial position. These filings also explain Amgen’s use of non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP operating expenses and Free Cash Flow. The company outlines which acquisition-related expenses, restructuring charges and other items are excluded from GAAP results and how the related tax effects are calculated.
On this page, users can review Amgen’s current and historical SEC documents, including Forms 10-K and 10-Q when available, 8-Ks for earnings and other material events, and additional filings that may address debt offerings, governance matters or other disclosures. Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly understand topics such as segment performance, non-GAAP adjustments, liquidity metrics and risk factor discussions without reading every page.
The filings page also surfaces information relevant to questions about AMGN stock, such as how management describes its financial performance, what non-GAAP metrics it emphasizes and how it discusses acquisition-related charges and restructuring initiatives. Real-time updates from EDGAR, combined with AI-generated overviews, allow investors to follow new Amgen filings as they appear and to place each document in the context of the company’s broader financial and regulatory history.
Amgen Inc. executive Murdo Gordon reported a routine tax-related share disposition. On March 16, 2026, the EVP, Global Commercial Operations delivered 6,691 shares of Amgen common stock at $366.21 per share to cover tax obligations, rather than selling them on the open market.
Following this tax-withholding disposition, Gordon directly holds 50,292 Amgen shares. His holdings also include 825 dividend equivalent units tied to unvested restricted stock units, which will be paid out in Amgen common stock as those awards vest.
Amgen Inc.’s Chairman, CEO and President Robert A. Bradway reported a tax-related share disposition. On March 16, 2026, 21,294 shares of Amgen common stock were withheld at $366.21 per share to cover tax obligations, a non-market transaction classified as a tax-withholding disposition. Following this, Bradway directly holds 501,862 shares of common stock. He also reports indirect holdings of 60,060 shares by a GRAT, 60,060 shares by a spousal GRAT, and 29,940 shares by his spouse. The direct holdings include 2,696 dividend equivalents that will settle in shares as related restricted stock units vest.
Amgen Inc. vice president, finance and chief accounting officer Matthew C. Busch reported a small tax-related share disposition. On the reported date, 327 shares of Amgen common stock were withheld at a price of $366.21 per share to satisfy tax obligations, classified as a tax-withholding disposition rather than an open-market sale.
After this transaction, Busch directly held 4,048 shares of Amgen common stock. His holdings include 68 dividend equivalents credited under Amgen’s equity incentive plan, which will be paid out in common shares as related restricted stock units vest.
Amgen Inc. Chairman, CEO and President Robert A. Bradway reported several equity transactions in the company’s stock. He exercised stock options, receiving 119,782 shares of common stock at $156.35 per share through a derivative exercise.
To cover the option exercise price and related tax withholding, 84,285 shares of common stock were withheld by the company and disposed of under a tax-withholding arrangement. After these transactions, Bradway directly owned 492,643 shares of Amgen common stock, and also had indirect ownership of 90,000 shares held through a GRAT and a spousal GRAT.
The directly owned shares include 2,414 dividend equivalents tied to unvested restricted stock units, which will be paid in Amgen common stock on a one-to-one basis as those units vest.
Santos Esteban reported acquisition or exercise transactions in this Form 4 filing.
Amgen executive Esteban Santos reported an equity award of 11,259 shares of common stock granted on 2026-03-03. The grant was recorded at a stated price of $0.00 per share as a stock award, bringing his directly held Amgen shares to 87,877.
The direct holdings figure includes 624 Dividend Equivalents credited under Amgen’s 2009 Equity Incentive Plan, which pay out in common stock as related RSUs vest, with cash paid for any remaining fractional share amount. Separately, Santos has indirect holdings representing 903.8036 shares through the company’s 401(k) plan stock fund.
REESE DAVID M reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. executive David M. Reese, EVP & Chief Technology Officer, reported an equity award of 12,063 shares of common stock on March 3, 2026. The award was recorded at $0.00 per share, reflecting a grant rather than an open‑market purchase.
After this grant, Reese directly owned 47,650 Amgen common shares. This total includes 667 Dividend Equivalents (DEs) credited under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which pay out in shares according to the vesting schedule.
Amgen Inc. senior vice president of human resources Derek Miller reported an award of 3,484 shares of Amgen common stock on March 3, 2026. The shares were acquired at a stated price of $0.00 per share as a grant or similar equity award, bringing his directly held common stock to 13,744 shares after the transaction.
The reported holdings include 176 dividend equivalents granted under Amgen’s equity incentive plan, which are credited to Miller’s unvested restricted stock units and paid out in common shares on a one‑to‑one basis as those units vest.
Amgen Inc. senior vice president of business development Rachna Khosla received an equity award of 1,876 shares of common stock on March 3, 2026, reported as a grant, award, or other acquisition with no purchase price. After this award, her directly held common stock position increased to 8,972 shares.
This total includes 107 dividend equivalents credited under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan. These dividend equivalents are tied to unvested restricted stock units and will be paid out in Amgen common shares on a one-to-one basis as the underlying awards vest, with cash paid for any remaining fractional share amounts.
Amgen Inc. senior vice president and chief compliance officer Nancy A. Grygiel received an equity award of 2,010 shares of Amgen common stock on March 3, 2026. The award is recorded at a price of $0.00 per share, reflecting a grant rather than an open-market purchase.
After this grant, she directly holds 9,249 Amgen shares. A footnote states this total includes 110 dividend equivalents credited under Amgen’s equity incentive plan, which convert to common shares as related restricted stock units vest. She also indirectly holds 105.465 Amgen shares through the company’s 401(k) plan stock fund.
Amgen Inc. executive vice president and CFO Peter H. Griffith reported an equity award of 12,063 shares of common stock on a Form 4. The shares were acquired as a grant at no cash cost, increasing his directly held stake to 54,587 shares.
The reported holdings include 676 dividend equivalent units granted under Amgen’s 2009 Equity Incentive Plan. These dividend equivalents are credited to his unvested restricted stock units and will be paid out in Amgen common shares on a one-for-one basis as the underlying awards vest, with cash paid for any remaining fractional share amounts.